{"organizations": [], "uuid": "379689f896038ee100e34cb1eec61358e364a1e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-theratechnologies-announces-fda-ap/brief-theratechnologies-announces-fda-approval-of-trogarzo-injection-idUSASB0C90X", "country": "US", "domain_rank": 408, "title": "BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-03-07T04:18:00.000+02:00", "replies_count": 0, "uuid": "379689f896038ee100e34cb1eec61358e364a1e2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-theratechnologies-announces-fda-ap/brief-theratechnologies-announces-fda-approval-of-trogarzo-injection-idUSASB0C90X", "ord_in_thread": 0, "title": "BRIEF-Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "theratechnologies inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Theratechnologies Inc:\n* THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZOâ„¢ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T04:18:00.000+02:00", "crawled": "2018-03-06T22:44:55.000+02:00", "highlightTitle": ""}